Celularity Presents Data On T-Cell Therapy Platform At ASCO Annual Meeting; PT-CD16VS Shows Potent Activity And Potential For Combination With Monoclonal Antibodies To Target Multiple Cancers
Celularity Presents Data On T-Cell Therapy Platform At ASCO Annual Meeting; PT-CD16VS Shows Potent Activity And Potential For Combination With Monoclonal Antibodies To Target Multiple Cancers
Celularity在ASCO年會上展示了T細胞治療平台的數據。PT-CD16VS具有強大的活性和與單克隆抗體組合治療多種癌症的潛力。
Celularity Presents Data On T-Cell Therapy Platform At ASCO Annual Meeting; PT-CD16VS Shows Potent Activity And Potential For Combination With Monoclonal Antibodies To Target Multiple Cancers
Celularity在ASCO年會上介紹了T細胞治療平台的數據；PT-CD16VS顯示出強大的活性和與單克隆抗體聯合作用的潛力以便於治療多種癌症。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。